At what enterprise value was RESONETICS acquired in 2021?

During the acquisition of RESONETICS by THE CARLYLE GROUP / GTCR in 2021, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b USD.

When was RESONETICS acquired by THE CARLYLE GROUP / GTCR?

RESONETICS was acquired by THE CARLYLE GROUP / GTCR in 2021.

How is the data for the RESONETICS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the RESONETICS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.carlyle.com/media-room/news-release-archive/carlyle-and-gtcr-announce-strategic-investment-resonetics

← DATABASE

Home Database Healthcare & PharmaRESONETICS

12/2021

RESONETICS acquired by THE CARLYLE GROUP & GTCR

UNITED STATES Life Sciences / Medical Devices EV 1b - 4b USD

Context

The strategic investment in Resonetics by Carlyle signifies a major territorial and technical advancement for the organization, building upon the momentum of eight successful add-on acquisitions. The strategic rationale for this transaction centers on a "platform-acceleration" maneuver, merging the target's industry-leading technical operational depth in micro-manufacturing with the new sponsor’s extensive global network and expertise in healthcare digitalization. This alignment provides the organization with the scientific talent and technological hardware required to address the increasing clinical demand for miniaturized, minimally invasive interventional components.

RESONETICS, which reported an EBITDA margin of in 2021, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Resonetics is a Medical Device Contract Manufacturing company based in the USA, specializing in the high-precision micro-manufacturing of components for interventional medical devices. The organization operates as a primary innovation partner for global medtech OEMs, focusing on laser processing, nitinol shaping, and centerless grinding for minimally invasive applications. Rather than focusing on commodity hardware, the firm thrives on a philosophy of technical operational depth, providing sophisticated engineering solutions for miniaturized devices in neurovascular and cardiovascular therapies. Its utility resides in its ability to support customers across the entire product lifecycle, from initial design and development in specialized labs to high-volume manufacturing.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2021

2020

Other operations with RESONETICS

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2026	RESONETICS	RESOLUTION MEDICAL	UNITED STATES	Medical Devices
10/2023	RESONETICS	NITINOL BUSINESS	UNITED STATES	Medical Devices

REFERENCES

Valuation range: EV 1b - 4b USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of RESONETICS by THE CARLYLE GROUP / GTCR are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: resonetics

Acquirer: the carlyle group / gtcr